Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies.
about
Genotoxic anti-cancer agents and their relationship to DNA damage, mitosis, and checkpoint adaptation in proliferating cancer cellsPharmacodynamic and therapeutic investigation of focused ultrasound-induced blood-brain barrier opening for enhanced temozolomide delivery in glioma treatment.Temozolomide followed by combined immunotherapy with GM-CSF, low-dose IL2 and IFN alpha in patients with metastatic melanoma.Trial of a 5-day dosing regimen of temozolomide in patients with relapsed small cell lung cancers with assessment of methylguanine-DNA methyltransferase.Evaluation of the exposure equivalence of oral versus intravenous temozolomide.Expression of miR-17-92 enhances anti-tumor activity of T-cells transduced with the anti-EGFRvIII chimeric antigen receptor in mice bearing human GBM xenograftsCombination of paclitaxel thermal gel depot with temozolomide and radiotherapy significantly prolongs survival in an experimental rodent glioma model.Combined PDK1 and CHK1 inhibition is required to kill glioblastoma stem-like cells in vitro and in vivoATM regulates 3-methylpurine-DNA glycosylase and promotes therapeutic resistance to alkylating agents.Overcoming multiple drug resistance mechanisms in medulloblastoma.Temozolomide. A new option for high-grade astrocytomas.Initial testing (stage 1) of temozolomide by the pediatric preclinical testing programSurvival and death strategies in glioma cells: autophagy, senescence and apoptosis triggered by a single type of temozolomide-induced DNA damage.Trimodal glioblastoma treatment consisting of concurrent radiotherapy, temozolomide, and the novel TGF-β receptor I kinase inhibitor LY2109761.Impact of phase II trials with progression-free survival as end-points on survival-based phase III studies in patients with anaplastic gliomas.Chemotherapeutic effect of a novel temozolomide analog on nasopharyngeal carcinoma in vitro and in vivo.Contributing factors of temozolomide resistance in MCF-7 tumor xenograft modelsAdvances in the management of glioblastoma: the role of temozolomide and MGMT testing.Management of glioblastoma.Methoxyamine sensitizes the resistant glioblastoma T98G cell line to the alkylating agent temozolomide.Chemoresistance to temozolomide in human glioma cell line U251 is associated with increased activity of O6-methylguanine-DNA methyltransferase and can be overcome by metronomic temozolomide regimen.Temozolomide-mediated DNA methylation in human myeloid precursor cells: differential involvement of intrinsic and extrinsic apoptotic pathways.Apoptosis triggered by DNA damage O6-methylguanine in human lymphocytes requires DNA replication and is mediated by p53 and Fas/CD95/Apo-1.Low Dose of Doxorubicin Potentiates the Effect of Temozolomide in Glioblastoma Cells.A novel stem cell culture model of recurrent glioblastoma.The clinical value of patient-derived glioblastoma tumorspheres in predicting treatment response.Optimal dynamic regimens with artificial intelligence: The case of temozolomide.
P2860
Q26851196-B14A15B6-B04E-4EF5-B341-46B6A8528CB0Q27322329-F9F62A86-794C-4E45-A2AF-A942B3D9FE25Q33346715-98D6C51A-3EB0-41A0-B7A9-50534C91FF47Q33417537-70384F96-A588-4707-90A4-E1B4353FFCDDQ33599155-DCA97995-DD6D-4E0B-A5C7-50A1ACB6EF28Q33606096-B1193ED9-193D-491A-889C-F45C9B473F2AQ33642356-295EF894-CF89-475B-AFAD-4F6AEF0CFA72Q33720256-F12E8FE6-5647-48CD-8C15-ECE8F76899B8Q34287713-6AFFEAF5-2070-450B-A6C5-A3DA8F2F83A6Q34500602-FB2BF1AD-5F51-4216-848D-5EB27DFE214FQ34566053-8634C312-6C71-414C-9379-D18B127FA292Q34571940-9397A784-09B6-4C48-BB5F-309711436689Q34576873-DC344200-E536-464D-94EA-99665CDFC440Q35042985-3562B551-6075-4055-B928-CE0653F87416Q35891348-4BB1BFEA-E2EB-4B6C-B271-1D6846A6C18FQ35965268-E0254A0F-33A5-4730-9333-B1E6FAD4306CQ36168735-46459E92-0342-4182-8E9B-72800CE267D2Q36500074-C6E26894-381F-4FFA-B2BC-0DC192D3785CQ37013025-1156ED79-3460-4E4A-8974-2461FFAB4843Q39308847-E17578C1-AFB3-4D42-B154-4A5FA6846994Q39479445-2FFB067A-07E9-4E13-BA10-674109DB642AQ43092195-4B59F2E3-1C08-4D32-8817-BAF3EADBAC0EQ44729054-C9A9D4E5-ACF0-4B84-9B11-8154410F80FAQ48763582-FF6B57EA-B675-4C2E-A4BF-9C8DEFEFCD21Q52147578-49501B1D-ED86-43D1-AAD6-9B72B9A566B7Q53750643-B29ACEEC-90A8-4142-8965-B40DA8661CA5Q55450692-1DADEEB4-38E7-4814-87AA-2ECFF4A5BB5F
P2860
Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies.
description
1999 nî lūn-bûn
@nan
1999 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Phase I and pharmacokinetic st ...... h advanced solid malignancies.
@ast
Phase I and pharmacokinetic st ...... h advanced solid malignancies.
@en
Phase I and pharmacokinetic st ...... h advanced solid malignancies.
@nl
type
label
Phase I and pharmacokinetic st ...... h advanced solid malignancies.
@ast
Phase I and pharmacokinetic st ...... h advanced solid malignancies.
@en
Phase I and pharmacokinetic st ...... h advanced solid malignancies.
@nl
prefLabel
Phase I and pharmacokinetic st ...... h advanced solid malignancies.
@ast
Phase I and pharmacokinetic st ...... h advanced solid malignancies.
@en
Phase I and pharmacokinetic st ...... h advanced solid malignancies.
@nl
P2093
P1476
Phase I and pharmacokinetic st ...... h advanced solid malignancies.
@en
P2093
D A Rinaldi
D D Von Hoff
E K Rowinsky
J R Eckardt
L A Hammond
P Reidenberg
P Statkevich
P304
P356
10.1200/JCO.1999.17.8.2604
P407
P577
1999-08-01T00:00:00Z